Last reviewed · How we verify
Prevention of venous thromboembolism in undergoing surgery
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of venous thromboembolism in undergoing surgery patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of venous thromboembolism in undergoing surgery treatment landscape brief
- Prevention of venous thromboembolism in undergoing surgery treatment updates RSS
Frequently asked questions about Prevention of venous thromboembolism in undergoing surgery
What drugs treat Prevention of venous thromboembolism in undergoing surgery?
Tracked treatments include Xarelto.
What is the treatment for Prevention of venous thromboembolism in undergoing surgery?
Standard treatment for Prevention of venous thromboembolism in undergoing surgery includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of venous thromboembolism in undergoing surgery patent cliff · Prevention of venous thromboembolism in undergoing surgery CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing